Zobrazeno 1 - 9 of 9 pro vyhledávání: '"S. M. Bhavnani"'
1
Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide
Autor: H. Ganesan, V. K. Gupta, M. C. Safir, S. M. Bhavnani, A. K. Talley, D. Melnick, C. M. Rubino
Publikováno v: Antimicrobial Agents and Chemotherapy.
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral (PO) carbapenem pro-drug that is converted to the active moiety tebipenem in the enterocytes. Tebipenem has activity against multidrug-resistant Gram-negative pathogens, including extended-spectr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee3d59d79db35045766797da940bf9f9
https://doi.org/10.1128/aac.01451-22
Zobrazit plný text záznamu
2
Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
Autor: M. Trang, E. A. Lakota, M. C. Safir, S. M. Bhavnani, L. Friedrich, J. N. Steenbergen, P. C. McGovern, E. Tzanis, C. M. Rubino
Publikováno v: Antimicrobial Agents and Chemotherapy. 67
Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subj
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2e770f144165854688a9d0e098510f41
https://doi.org/10.1128/aac.02397-21
Zobrazit plný text záznamu
3
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model
Autor: B. D. VanScoy, S. Jones, H. Conde, L. V. Friedrich, N. Cotroneo, S. M. Bhavnani, P. G. Ambrose
Publikováno v: Antimicrobial Agents and Chemotherapy.
Tebipenem is an orally bioavailable carbapenem in development for the treatment of patients with complicated urinary tract infections. Herein, we describe the results of studies designed to evaluate tebipenem’s potential as an oral (p.o.) transitio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4738368fe1e9a6ab1e01362a7eaca378
https://doi.org/10.1128/aac.00908-22
Zobrazit plný text záznamu
5
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
Autor: S. M. Bhavnani, M. Trang, D. C. Griffith, O. Lomovskaya, J. P. Hammel, J. S. Loutit, S. K. Cammarata, M. N. Dudley, P. G. Ambrose, C. M. Rubino
Publikováno v: Antimicrobial agents and chemotherapy. 66(12)
Meropenem-vaborbactam is a fixed-dose beta-lactam/beta-lactamase inhibitor with potent in vitro and in vivo activity against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales . Pharmacokinetic-pharmacodynamic (PK-PD) target attainm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff98121558f4e7675de0019cf37b559e
https://pubmed.ncbi.nlm.nih.gov/36374023
Zobrazit plný text záznamu
6
Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents
Autor: J. Wang, S. M. Bhavnani, S. H. Jang, Thomas P. Lodise, A. Dane, Matthew L. Rizk, Tina Guina, Ann E. Eakin, George L. Drusano, J. F. Tomayko, L. Zhuang
Publikováno v: Antimicrobial Agents and Chemotherapy
In June 2017, The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, organized a workshop entitled “Pharmacokinetics-Pharmacodynamics (PK/PD) for Development of Therapeutics against Bacterial Pathogens
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7430b17cf8ed1d389e90eab842afd9e5
https://doi.org/10.1128/aac.02309-18
Zobrazit plný text záznamu
7
Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally
Autor: G. M. Eliopoulos, G. L. Drusano, P. G. Ambrose, S. M. Bhavnani, J. S. Bertino, A. N. Nafziger, A. Louie
Publikováno v: Clinical Infectious Diseases. 45:753-760
Gram-negative organisms have become increasingly resistant to both b-lactam antibiotics and fluoroquinolones. Consequently, aminoglycoside antibiotics have undergone a resurgence in use. Because of the known toxicities of aminoglycoside antibiotics,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eebdaea1f13776d1ba625762bfbf0701
https://doi.org/10.1086/520991
Zobrazit plný text záznamu
8
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program
Autor: P G, Ambrose, S M, Bhavnani, R N, Jones
Publikováno v: Antimicrobial agents and chemotherapy. 47(5)
The frequency of resistance to beta-lactams among nosocomial isolates has been increasing due to extended-spectrum beta-lactamase (ESBL)-producing enteric bacilli. Although clinical outcome data are desirable, assessment of clinical efficacy has been
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a54f9bb37da01853407947811af1e8d4
https://pubmed.ncbi.nlm.nih.gov/12709334
Zobrazit plný text záznamu
9
Antipsychotic agents: a survey of the prevalence, severity and burden of side effects
Autor: S M, Bhavnani, G M, Levin
Publikováno v: International clinical psychopharmacology. 11(1)
We prospectively studied 64 male veteran out-patients with psychotic illnesses receiving one of six antipsychotic agents grouped by potency (low, mid, high, atypical) to determine: (1) prevalence of side effects; (2) cumulative side effect burden; an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::75a9068939bc1d3424c087fd4572ce5d
https://pubmed.ncbi.nlm.nih.gov/8732308
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje